GlassScriptPhysician profile
Michael P Kosty
NPI 1801857099
$82,169.17
in general payments reported to CMS, 2019-2025
71 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,597 · 2020: $4,641 · 2021: $22K · 2022: $10K · 2023: $38K · 2024: $3,467 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Honoraria: $7,000 · Food and Beverage: $5,098 · Consulting Fee: $3,930 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500 · Travel and Lodging: $934 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,781.50 |
| Honoraria | $7,000.00 |
| Food and Beverage | $5,098.40 |
| Consulting Fee | $3,930.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
| Travel and Lodging | $933.71 |
| Education | $108.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $22,032.30 | 2023 | Krazati |
| Philips North America LLC | $20,500.00 | 2021-2023 | |
| Myovant Sciences INC. | $7,669.77 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $3,602.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $3,063.18 | 2019-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $3,051.17 | 2019-2024 | Ninlaro, Alunbrig |
| Daiichi Sankyo INC. | $2,484.52 | 2019-2024 | Enhertu |
| Janssen Biotech, INC. | $2,165.43 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Gilead Sciences, INC. | $2,103.82 | 2019-2024 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,769.60 | 2019-2023 | Gilotrif |
| Merck Sharp & Dohme LLC | $1,705.18 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $1,632.97 | 2019-2024 | Tagrisso, Imfinzi, Calquence |
| Beigene, LTD. | $1,484.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,042.69 | 2019-2024 | Opdivo, Opdualag, Reblozyl |
| Novartis Pharmaceuticals Corporation | $722.63 | 2019-2023 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $717.28 | 2019-2024 | |
| Amgen INC. | $532.75 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Pfizer INC. | $441.46 | 2019-2023 | |
| Genzyme Corporation | $406.34 | 2019-2024 | |
| Exelixis INC. | $380.99 | 2019-2024 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $375.85 | 2019-2024 | |
| Glaxosmithkline, LLC. | $351.87 | 2020-2024 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $349.52 | 2019-2023 | Retevmo, Jaypirca |
| Pharmaessentia USA Corporation | $246.60 | 2022-2024 | Besremi |
| Celgene Corporation | $218.95 | 2019-2024 | Pomalyst, Opdivo |
| Abbvie INC. | $198.42 | 2019-2025 | |
| Array Biopharma INC | $180.49 | 2019-2024 | Mektovi, Braftovi, Lorbrena |
| Foundation Medicine, INC. | $178.47 | 2019-2023 | |
| Genentech USA, INC. | $175.81 | 2019-2023 | Venclexta |
| Alexion Pharmaceuticals, INC. | $161.70 | 2019-2024 | Ultomiris |
| Astellas Pharma US INC | $155.28 | 2019-2025 | Xospata, Xtandi, Padcev |
| Beigene USA, INC. | $145.59 | 2023-2024 | Brukinsa |
| Emd Serono, INC. | $138.96 | 2019-2024 | |
| Coherus Oncology, INC. | $113.94 | 2023-2024 | |
| Tersera Therapeutics LLC | $112.42 | 2019-2023 | Xermelo, Zoladex |
| Stemline Therapeutics INC. | $108.74 | 2023 | Orserdu |
| Kite Pharma, INC. | $102.17 | 2020-2024 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $98.84 | 2019-2023 | Tazverik |
| Clovis Oncology, INC. | $89.59 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.84 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $76.33 | 2021-2022 | |
| Blueprint Medicines Corporation | $68.87 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $67.47 | 2019 | |
| Eusa Pharma (US) LLC | $62.53 | 2019 | |
| Seagen INC. | $62.40 | 2019-2023 | Adcetris, Padcev |
| Sun Pharmaceutical Industries INC. | $56.43 | 2019-2023 | Yonsa, Odomzo |
| Janssen Pharmaceuticals, INC | $55.89 | 2019-2023 | Xarelto |
| Incyte Corporation | $47.71 | 2019 | |
| Genmab U.S., INC. | $46.12 | 2023-2024 | Epkinly |
| Rigel Pharmaceuticals, INC. | $42.45 | 2023 | Tavalisse, Rezlidhia |
| Accord Healthcare, INC. | $41.61 | 2023-2024 | |
| Kyowa Kirin, INC. | $40.13 | 2020-2024 | Poteligeo |
| Taiho Oncology, INC. | $39.65 | 2019-2023 | |
| Tempus Ai, INC | $38.35 | 2024 | |
| Sumitomo Pharma America, INC. | $38.13 | 2023 | Orgovyx |
| Springworks Therapeutics, INC. | $34.24 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $30.04 | 2023 | Qinlock |
| Cti Biopharma Corp. | $28.23 | 2023 | Vonjo |
| Sobi, INC | $28.09 | 2023 | |
| Servier Pharmaceuticals LLC | $24.85 | 2023 | |
| Puma Biotechnology, INC. | $21.32 | 2023 | |
| Dova Pharmaceuticals | $19.81 | 2020 | |
| Acrotech Biopharma INC. | $19.00 | 2023 | Beleodaq |
| Csl Behring | $16.55 | 2024 | Afstyla, Idelvion |
| Heron Therapeutics, INC. | $16.38 | 2019 | |
| Spectrum Pharmaceuticals INC. | $15.49 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.10 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.56 | 2023 | Pyrukynd |
| Advanced Accelerator Applications | $12.65 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kosty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.